Bluejay Therapeutics is planning an IPO in the US, targeting $150 million.

Investing.com -- Bluejay Therapeutics, a pharmaceutical company specializing in severe viral and liver diseases, is reportedly planning an initial public offering (IPO) in the U.S., according to Bloomberg News sources. The company could go public as soon as next month, with reports indicating that Bluejay is collaborating with JPMorgan Chase & Co., Jefferies Financial Group Inc., and Cantor Fitzgerald for the potential IPO. The goal is to raise at least $150 million through this offering.

Discussions are still ongoing, and details such as the size and timeline of the IPO may change. Representatives from Bluejay, Cantor Fitzgerald, JPMorgan, and Jefferies declined to comment on the matter. This article has been created with the assistance of artificial intelligence, translated, and reviewed by an editor. For more information, please refer to our Terms and Conditions section.